


### A 3-Way Train Wreck on P450IID6: Kevin Eric Saunders, Jan-Feb 1997:

The elimination of mCPP, the principal metabolite of the "Sleeping Aid" Trazodone (Desyrel®), is potently inhibited by the "Antidepressant" Fluoxetine (Prozac®), its metabolite Norfluoxetine, and the "Sleeping Aid" Hydroxyzine (Vistaril®).



"It is well known that central serotonin agonists such as LSD and MCPP as well as dopamine agonists such as amphetamine and cocaine are capable of producing psychotic reaction (Huttunen 1995)."

"Clinical Psychopharmacology Seminar: Atypical Neuroleptics"

Paul Perry, Ph.D, BCPP, Brian C. Lund, Pharm.D.

University of Iowa Health Care. Peer Review Status: Internally Peer Reviewed.

"Even in low dosages, [antihistamines] are associated with impairment of daytime functioning. Furthermore, the anticholinergic effects of antihistamines (delirium, confusion, disorientation, etc.) may exacerbate problem behaviors."

"Appropriate Use of Psychotropic Drugs in Nursing Homes"

Tatyana Gurvich, Pharm.D., and Janet A. Cunningham, M.D., M.P.H.

American Family Physician, March 1, 2000

**Table 1. Cytochrome P450 Enzymes and Drug-Drug Interactions**

Function	IIC9	IIC19	IID6	Metab	IIIA4
Substrate	THC				(THC/CBD?)
Substrate			mCPP	<- 100% 3A4	<- Trazodone
Substrate	Fluoxetine		Fluoxetine		
Substrate			Hydroxyzine		
Inhibitor		Fluoxetine	++Fluoxetine++	-> 2C9	-> ++Norfluoxetine++
Inhibitor			++Norfluoxetine++		
Inhibitor			+Hydroxyzine+		
Inhibitor	CBD?	CBD?			CBD
GENETICS	C 10	C 10	C 22		C 7
%PM	Polymorphic 1-3% Cauc.	Polymorphic 3-5% Cauc.	Polymorphic 5-10% Cauc.		
(Poor Metabolizers)		15-20% Asian	(20% German)		

**Table 2. in Vivo Study of the Effects of Fluoxetine on blood plasma levels of mCPP**

Author	N	SSRI Treatment Dose (mg/day) x Duration (days)	Substrate Dosing	Substrate	(AUC2-AUC1)+AUC1
Maes	11	20 x 28	mCPP	7 days	820% (270%/3,295%) <sup>‡</sup>

<sup>‡</sup> 820% is based on all the data. If the two highest increases are excluded, the average was 270%. The two highest increases averaged 3,295%.

Adapted from: Preskorn SH. J Psychopharmacology. 1998;12:S89-S97.